32.5 C
Vientiane
Wednesday, August 20, 2025
spot_img
Home Blog Page 26

KELUN-BIOTECH ANNOUNCES 2025 INTERIM RESULTS

  • Revenue reached approximately RMB950.4 million, with total commercial sales RMB309.8million, representing a significant increase in proportion
  • Research and development expenses was approximately RMB611.5 million
  • Loss for the period was RMB145.2 million; adjusted loss for the period[1] was RMB69.4 million
  • Cash and cash equivalents[2] amounted to approximately RMB4527.8 million, reflecting ample cash reserves

Note1: Calculated by deducting equity-settled share-based payment from loss for the year.

Note2: Comprises cash and cash equivalents, restricted deposits, financial assets measured at fair value through profit or loss, financial assets measured at amortized cost and financial assets measured at fair value through other comprehensive income.

 

CHENGDU, China, Aug. 18, 2025 /PRNewswire/ — Sichuan Kelun-Biotech Pharmaceutical Co., Ltd. (“Kelun-Biotech” or the “Company“, Stock Code: 6990.HK) announced its unaudited interim results for the six months ended 30 June 2025 (the “Reporting Period“).

In the first half of 2025, China’s biopharmaceutical industry reached an inflection point for high-quality growth, driven by accelerated innovation in drug research and development, the rollout of favorable policies, increasing momentum in industry collaboration and mergers and acquisitions. Kelun-Biotech capitalized on these opportunities by its proprietary technology platforms, innovation-led R&D, and a well-established commercialization infrastructure. These elements have worked together to enable the Company to establish a fully integrated model covering R&D, clinical development, manufacturing, and commercialization.

Focusing on addressing significant unmet medical needs in both oncology (such as breast cancer (BC), non-small cell lung cancer (NSCLC), and gastrointestinal (GI) cancers including gastric cancer (GC) and colorectal cancer (CRC)) and non-oncology diseases, the Company has developed a rich and diverse pipeline of over 30 candidates. More than 10 of these candidates have already entered clinical stage. At the same time, the Company continues to invest in next-generation conjugation technologies and a diversified portfolio of assets, aiming to deliver innovative therapies for patients worldwide and contribute to the improvement of global healthcare.

ADC & novel DC assets breakthroughs are redefining the treatment landscape.

sac-TMT (sacituzumab tirumotecan, SKB264/MK-2870,佳泰萊®)

The first TROP2 ADC drug approved for marketing in LC globally.

TNBC: Approved by the National Medical Products Administration (“NMPA”) for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies. The Company has initiated a Phase 3 registrational study of sac-TMT monotherapy versus investigator-choice chemotherapy for 1L advanced TNBC.

HR+/HER2- BC. In May 2025, the NDA for sac-TMT for the treatment of adult patients with unresectable locally advanced or metastatic HR+/HER2- BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting was accepted by the NMPA, and was included in the priority review and approval process. A Phase 3 registrational study of sac-TMT versus investigator’s choice of chemotherapy for treatment of patients with unresectable locally advanced, recurrent or metastatic HR+/HER2- BC who received prior endocrine therapy is in progress.

EGFR-mutant NSCLC. In March 2025, the Company received marketing authorization in China from the NMPA for sac-TMT for the treatment of adult patients with EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy. Sac-TMT monotherapy demonstrated a statistically significant and clinically meaningful improvement in ORR, PFS and OS compared with docetaxel. In addition, a Phase 3 registrational study of sac-TMT combined with osimertinib as first-line treatment of locally advanced or metastatic non-squamous EGFR-mutant NSCLC is in progress.

EGFR-wild type NSCLC. Two Phase 3 registrational studies of sac-TMT in combination with pembrolizumab are in progress. In June 2025, sac-TMT in combination with tagitanlimab was granted Breakthrough Therapy Designation by the NMPA for the first-line treatment of locally advanced or metastatic non-squamous NSCLC without actionable genomic alterations.

Other indications. The Company is actively exploring the potential of sac-TMT both as a monotherapy and in combination with other therapies for treating other solid tumors, including GC, EC, CC, OC, UC, CRPC and HNSCC.

Global clinical development. As of August 18, 2025, MSD is progressing 14 ongoing Phase 3 global, multi-center clinical studies for sac-TMT for several types of cancer including BC, LC, gynecological cancer and GI cancer. The Company is also collaborating with MSD on several global Phase 2 basket studies for sac-TMT as monotherapy or in combination with other agents for multiple solid tumors and those studies are ongoing.

Trastuzumab Botidotin (HER2 ADC, A166, 舒泰萊®[1])

In January 2025, an NDA for the treatment of adult patients with HER2+ unresectable or metastatic BC who have received at least one prior anti-HER2 therapy was accepted by the CDE of the NMPA.

Trastuzumab botidotin has met the primary endpoints of its pivotal Phase 2 trial for 3L+ and advanced HER2+ BC based on results from the primary analysis, and the NDA has been submitted to the NMPA.

The Company has initiated an open, multicenter Phase 2 clinical study of trastuzumab botidotin in the treatment of HER2+ unresectable or metastatic BC that previously received a topoisomerase 1 inhibitor ADC.

[1] The name of the product is subject to the approval of NMPA

Other ADC Products

SKB315 (CLDN18.2 ADC): the company is conducting a Phase 1b clinical trial of SKB315 and have initiated the exploration in combination with immunotherapy for the treatment of GC/GEJC. Results of a Phase 1 study of SKB315 will be presented at 2025 ESMO Congress in October 2025.

SKB410/MK-3120 (Nectin-4 ADC): has shown promising Phase 1 clinical data. MSD, as the partner, has launched the global Phase 1/2 clinical trial of SKB410.

SKB571/MK-2750: a novel bsADC that primarily targets various solid tumors such as LC and CRC etc. being developed in collaboration with MSD. The Phase 2 clinical trial in China is to be initiated.

SKB518, SKB535/MK-6204 and SKB445: novel ADC drugs with potential FIC targets. The Phase 2 clinical trial for SKB518 and the Phase 1 clinical trials for SKB535 and SKB445 are ongoing in China. The Company has entered into a license and collaboration agreement with MSD to develop SKB535.

SKB500 and SKB501: novel ADC drugs with verified targets but differentiated payload-linker strategies. The company been received a clinical trial notice approving the IND application of SKB501 and SKB500, respectively, for advanced solid tumors from the NMPA.

SKB107: a RDC drug jointly developed by the Company and the Affiliated Hospital of Southwest Medical University (西南醫科大學附屬醫院) targeting bone metastases in solid tumors. In March 2025, an IND application for SKB107 was approved by the NMPA and the Phase 1 study is ongoing.

Non-DC asset advancements are diversifying the innovation pipeline.

Tagitanlimab (PD-L1 mAb; A167; 科泰莱®):

The first PD-L1 mAb globally to receive authorization for the first-line treatment of NPC.

We have received marketing authorization of tagitanlimab in China from NMPA for the treatment of patients with recurrent or metastatic NPC who have failed after prior 2L+ chemotherapy. In January 2025, we received marketing authorization of tagitanlimab used in combination with cisplatin and gemcitabine for the first-line treatment of patients with recurrent or metastatic NPC in China from NMPA.

Cetuximab N01 (EGFR mAb; A140; 达泰莱®)

An EGFR mAb compared with Cetuximab Solution for Injection (Erbitux®)

In February 2025, we received marketing authorization in China from the NMPA for Cetuximab N01 Injection used in combination with FOLFOX or FOLFIRI regimens for first-line treatment of RAS wild-type mCRC.

A400/EP0031 (RET inhibitor): The Company is currently conducting pivotal clinical studies for 1L & 2L+ advanced RET+ NSCLC as well as a Phase 1b/2 clinical study for RET+ MTC and solid tumor in China. Through the Company’s collaboration and license agreement, Ellipses Pharma is progressing their phase 2 clinical study globally outside of China. 

SKB378/WIN378 (TSLP mAb): In January 2025, an IND application for SKB378 for the treatment of COPD was approved by the NMPA. The Company’s collaboration partner, Windward Bio, has launched the Phase 2 POLARIS trial in patients with asthma.

SKB336 (FXI/FXIa mAb): The Phase 1 clinical trial has been completed in China.

A296 (STING agonist): A Phase 1 trial is being carried out in China.

Commercialization Accelerates: Sales & Market Access Expanding Footprint

Sac- TMT (佳泰莱®), tagitanlimab (科泰莱®) and Cetuximab N01 (达泰莱®) have been successively launched, marking the full-scale initiation of commercialization. The Company expects to launch trastuzumab botidotin (舒泰莱®) in the China market and file one NDA for A400 in the second half of 2025.

Sales performance: The total commercial sales reached RMB309.8 million for the first half of 2025. Among them, the sales of sac-TMT (佳泰莱®) accounted for 97.6%. At the same time, all accounts receivables from sales of pharmaceutical products were collected within the payment period, ensuring efficient and stable cash flow.

Market coverage and academic promotion: Currently, the company’s businesses have covered 30 provinces, over 300 prefectures, and over 2,000 hospitals, where over 1,000 hospitals generated sales, and reached tens of thousands of healthcare professionals through various types of marketing campaigns to convey product and medical professional information. In addition, the company has obtained authoritative endorsement for its products from experts in clinical guidelines, providing further support for the commercialization process. 

Commercialization system: The Company has established a fully-fledged marketing team of over 350 people, with a departmental structure that includes marketing, sales, medical affairs, strategic planning and commercial excellence, among other departments, as well as marketing compliance and KA functions. Through the efficient execution of the marketing team, the company has established relationships with multiple leading commercial and distribution groups, including 60+ Tier 1 distributors and 400+ DTP pharmacies. A hierarchical management system for pharmacy retail has been adopted and trainings have been provided to around 4,500 pharmacists in the first half of 2025. By organizing nationwide pharmacy trainings, the company has significantly enhanced the professionalism of terminal services and improved the ability to provide patients with medication guidance.

Market access: In the first half of 2025, sac-TMT (佳泰莱®), tagitanlimab (科泰莱®) and Cetuximab N01 (达泰莱®) have been included in 29, 25 and 15 provincial networks, respectively, ensuring rapid market access through provincial procurement channels. Meanwhile, preparations for the National Reimburesement Drug List (國家醫保藥品目錄) access of marketed products are underway. Currently, sac-TMT (佳泰莱®), tagitanlimab (科泰莱®) and Cetuximab N01 (达泰莱®) have all passed the preliminary formal examination of National Reimbursement Drug List.

Meanwhile, to further reduce the burden of patients and implement the concept of inclusive healthcare, the company been proactively facilitating the enrollment of sac-TMT (佳泰莱®) in provincial and prefecture city level Inclusive Insurance (惠民保). As at the end of the Reporting Period, sac-TMT (佳泰莱®) has been enrolled in more than 7 provinces and 20 cities.

Global market: Globally, we will continue to pursue a flexible strategy to capture the commercial value in major international markets, through forging synergistic license and collaboration opportunities worldwide.

Global Collaboration Network Expansion & Authoritative Industry Recognition

In the first half of 2025, the Company continued to expand its global collaboration network and deepen partnerships. Working closely with collaborators, it is advancing clinical research worldwide with the goal of maximizing the global value of its pipeline, delivering high-quality medical solutions to patients, and strengthening its leading position in the biopharmaceutical sector.

Collaboration with MSD: As of the date of this announcement, MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as monotherapy or in combination with pembrolizumab or other agents, for several types of cancer including BC, LC, gynecological cancer and GI cancer.

In addition to sac-TMT, the Company is also collaborating with MSD on certain ADC assets including SKB410/MK-3120, SKB571/MK-2750, SKB535/MK-6204, etc. to continuously explore favorable ADC pipeline portfolios.

Collaboration with Ellipses Pharma: The Company has deepened its collaboration with Ellipses Pharma on A400/EP0031, which has been cleared by the FDA to progress into Phase 2 clinical development. As of June 30, 2025, Ellipses Pharma had set up a total of 36 clinical sites in the United States, Europe and UAE for EP0031.

Collaboration with Windward Bio: In January 2025, the Company and Harbour BioMed had entered into an exclusive license agreement with Windward Bio, under which the Company and Harbour BioMed granted Windward Bio an exclusive license for the research, development, manufacturing and commercialization of SKB378/WIN378 globally (excluding Greater China and several Southeast and West Asian countries).

In the first half of 2025, the Company earned high recognition from professional institutions and industry associations for its outstanding corporate management, product innovation, and strong performance in the capital market. In May 2025, the Company received “Asia’s Best Company” award from FinanceAsia (亞洲金融), as well as a series of awards from Extel, including “Most Honored Company”, “Best Company Board”, “Best CEO”, “Best CFO”, “Best ESG” and etc.. The Company was also awarded “IRM OF CHINESE LISTED COMPANIES” by Securities Times (證券時報). In July 2025, the Company was recognized with the “China Pharmaceutical Emerging Innovative Force Award” by the China National Pharmaceutical Industry Information Center (中國醫藥工業信息中心).

Additionally, the Company continues to strengthen its ESG strategy and improve its ESG governance structure to support sustainable development. The Company has established a comprehensive three-tier ESG governance structure consisting of the Board of Directors, ESG Working Group and ESG Executive Body. Through the establishment and continuous improvement of the ESG governance structure, the Company comprehensively enhances ESG performance ability.

Outlook

In the second half of 2025, the Company will continue to advance its differentiated pipelines targeting indications with significant medical needs, innovate and optimize payload-linker strategies, novel DC designs and structures, and expand application to non-oncology diseases. Meanwhile, the Company will further enhance its end-to-end drug development capabilities, advance towards commercialization and actively expand global footprints and strategic partnerships to maximize the value of its pipelines. In addition, the Company will continuously optimize its operation system to become a leading global biopharmaceutical company.

About Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (referred to as “Kelun-Biotech” Stock Code: 6990.HK) is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd., specializing in the R&D, production, commercialization, and international collaboration of innovative biotechnology and small-molecule drugs. The Company focuses on addressing unmet clinical needs both globally and in China, with a strategic emphasis on major disease areas such as oncology, autoimmune disorders, inflammation, and metabolic diseases. It is dedicated to building an international platform for drug R&D and industrialization, with the aim of becoming a global leader in the innovative drug sector. Currently, Kelun-Biotech has over 30 key innovative drug projects, including 3 projects that have received market approval, 1 project at the NDA stage, and more than 10 projects in clinical trials. The Company has also successfully established its internationally renowned proprietary ADC development platform, OptiDCTM, with 1 ADC project approved for market launch, 1 ADC project at the NDA stage, and several ADC or novel ADC projects in clinical or preclinical development. For more information, please visit the official website: https://kelun-biotech.com/

For further information, please contact:

Wonderful Sky Financial Group Ltd.
Angie Li & Jason Lai
Tel: (852) 6150 8598 / (852) 9798 0715
Email: po@wsfg.hk 

India’s leading healthcare network Manipal Hospitals welcomes India’s leading cancer specialist Dr. Surender Kumar Dabas to strengthen robotic cancer care in Delhi NCR

NEW DELHI, Aug. 18, 2025 /PRNewswire/ — Manipal Hospitals, one of India’s leading and globally recognized healthcare institutions, welcomes one of India’s most renowned robotic oncosurgeons, Dr. Surender Kumar Dabas as Chairman – Manipal Comprehensive Cancer Centre and Onco Robotic Surgeries, North-West Cluster. With this addition, the hospital across Delhi, Gurugram and Ghaziabad further reinforces its vision to be a destination for world-class cancer care, catering to patients across India as well as international geographies.

Dr. Surender Kumar Dabas, Chairman - Manipal Comprehensive Cancer Centre and Onco Robotic Surgeries, North-West Cluster
Dr. Surender Kumar Dabas, Chairman – Manipal Comprehensive Cancer Centre and Onco Robotic Surgeries, North-West Cluster

Dr. Surender Dabas brings with him more than 22 years of experience in surgical oncology and has been a pioneer in the field of robotic head and neck cancer surgery. Over the years, he has performed over 30,000 cancer surgeries, including more than 4,000 robot-assisted procedures, making him one of the most experienced robotic oncosurgeons in India. His expertise spans robot-assisted surgeries for head and neck cancer, thoracic cancer, gynaecologic malignancies, urological cancer, gastrointestinal and colorectal cancer, and breast cancer.

Welcoming the doctor, Mr. Pramod Alagharu, Regional COO North-West Cluster, Manipal Hospitals, said, “We are proud to welcome Dr. Surender Dabas and his strong team of 150 medical experts. With his specialized expertise in managing complex cancer procedures, Dr. Dabas brings immense value to our commitment to delivering world-class healthcare, including robot-assisted cancer treatment. His leadership will strengthen our role as a preferred destination for complex oncology cases for both domestic and international patients.

Speaking about his new role, Dr. Surender Kumar Dabas, Chairman Manipal Comprehensive Cancer Centre and Onco Robotic Surgeries, North-West Cluster added, “I am excited to join the Manipal family, one of the largest healthcare networks in India, which has a long-standing reputation for excellence in healthcare. My goal is to build on a strong foundation here and bring the most advanced and precise cancer care to both national and international patients. Through the use of robotics and newer technologies, we aim to make surgeries safer, less invasive, and more effective, improving both survival and quality of life for our patients.”

With Dr. Dabas leading the Manipal Comprehensive Cancer Centre, the hospital is poised to emerge as a centre of excellence in comprehensive cancer care, offering advanced clinical protocols, evidence-based treatment, and a multidisciplinary approach to managing cancer. This will further position Manipal Hospitals as a trusted partner for international patients seeking high-quality, technology-led cancer treatment in India.

For any inquiries, contact our team at query.mhd@manipalhospitals.com or call us +91 8527388881.

About Manipal Hospitals

As a pioneer in healthcare, Manipal Hospitals is among the top healthcare providers in India serving over 7 million patients annually. Its focus is to develop an affordable, high-quality healthcare framework through its multispecialty and tertiary care delivery spectrum and further extend it to out-of-hospital care. With the completion of the acquisition of Medica Synergie hospitals and AMRI Hospitals Limited (acquired in Sept 2023), the integrated network today has a pan-India footprint of 38 hospitals across 19 cities with 10,500+ beds and a talented pool of 7,200+ doctors and an employee strength of over 20,500.

Manipal Hospitals provides comprehensive curative and preventive care for a multitude of patients from around the globe. Manipal Hospitals is NABH and AAHRPP accredited, and most of the hospitals in its network are NABL, ER, and Blood Bank accredited and recognized for Nursing Excellence. Manipal Hospitals has also been recognized as the most respected and patient-recommended hospital in India through various consumer surveys.

 

KuCoin Pay Partners with Umy to Bring Crypto-Powered Travel to Life

PROVIDENCIALES, Turks and Caicos Islands, Aug. 18, 2025 /PRNewswire/ — KuCoin, a leading global cryptocurrency exchange, is pleased to announce that its payment arm KuCoin Pay has entered into a strategic partnership with Umy, an innovative Web3 travel and lifestyle platform. This collaboration aims to make travel more open, efficient, and rewarding by integrating secure, seamless cryptocurrency payments into Umy’s global travel booking ecosystem.


Through this integration, KuCoin users can now effortlessly book hotels, reserve flights, and access lifestyle services on Umy — all while paying with digital assets. Supporting over 50 cryptocurrencies, including KCS, USDT, USDC, and BTC, KuCoin Pay empowers travelers to enjoy frictionless transactions without the need for currency exchange or additional banking intermediaries.

“At KuCoin Pay, our mission is to bridge crypto with everyday life, and travel is one of the most exciting frontiers,” said Kumiko Ho, Head of Payment Business at KuCoin. “Our partnership with Umy allows users to unlock real-world experiences directly with their digital assets, offering more freedom, convenience, and value in every journey.”

“Umy is committed to making travel and lifestyle services accessible in the Web3 era,” said Alex Lee, Umy CEO. “By partnering with KuCoin Pay, we’re enabling travelers to seamlessly use their crypto assets for bookings, making the experience more efficient, borderless, and rewarding.”

To celebrate this partnership, KuCoin Pay and Umy are offering an exclusive limited-time promotion for KuCoin users until September 1, 2025. Users can get $20 off every $200 spent on hotels, flights, and more! See more details in the official announcement.

About KuCoin Pay
KuCoin Pay is a pioneering merchant payment solution that drives business growth by integrating cryptocurrency payments into retail ecosystems. Supporting over 50 cryptocurrencies including KCS, USDT, USDC, and BTC, KuCoin Pay enables seamless transactions for both online and in-store purchases globally.

For more information about KuCoin Pay, please visit https://www.kucoin.com/pay.

About Umy
Umy is an innovative Web3 global travel and lifestyle platform offering hotel bookings, flight reservations, and cryptocurrency payment solutions. Its mission is to connect on-chain digital assets with real-world experiences, making it effortless to travel, shop, and live using crypto in everyday life.

First Batch of 600 Yuchai-Powered Natural Gas Buses Order Delivered to Mexico

SINGAPORE, Aug. 18, 2025 /PRNewswire/ — China Yuchai International Limited (NYSE: CYD) (“China Yuchai” or the “Company”), one of the largest powertrain solution manufacturers through its main operating subsidiary in China, Guangxi Yuchai Machinery Company Limited (“Yuchai”), announced today that the first batch of buses powered by Yuchai’s natural gas engines was recently delivered to Nuevo León, Mexico, providing a stable and reliable power source to public buses for upgrading the local public transportation system. This batch is the first shipment under the 600-unit natural gas bus order received in 2024.

Currently, 1,400 buses powered by Yuchai natural gas engines are in active service across Nuevo León, Mexico and the total number is projected to exceed 2,500 by the end of 2025.

Since its first entry into the Mexican market, Yuchai’s natural gas bus engines have grown from a modest presence to a leading position in the Mexican natural gas bus engine market, becoming the supplier of choice for Mexican bus fleets. With strong aftersales service and a growing service network across Mexico, Yuchai is well recognized and supported by the market in Nuevo León—significantly adding value to the ‘Yuchai’ branding.

Mr. Weng Ming Hoh, President of China Yuchai, commented, “We are proud of being a reputable and reliable driving force in the ongoing development of Mexico’s sustainable public transportation industry. Yuchai’s increasing growth in overseas markets demonstrates our products’ superior quality and performance. Our commitment to aftersales service with a growing service network, ensures the availability of technical and parts in keeping our engines running.”  

About China Yuchai International

China Yuchai International Limited, through its subsidiary Guangxi Yuchai Machinery Company Limited (“Yuchai”), is one of the leading powertrain solution providers in China. Yuchai specializes in the design, manufacture, assembly, and sale of a wide variety of light-, medium- and heavy-duty engines for trucks, buses, pickups, construction and agricultural equipment, and marine and power generation applications. Yuchai offers a comprehensive portfolio of powertrain solutions, including but not limited to diesel, natural gas, and new energy products such as pure electric, range extenders, and hybrid and fuel cell systems.  Through its extensive network of regional sales offices and authorized customer service centers, Yuchai distributes its engines directly to auto OEMs and distributors while providing after-sales services across China and globally.  Founded in 1951, Yuchai has established a reputable brand name, built a strong research and development team, and achieved a significant market share in China. Known for its high-quality products and reliable after-sales support, Yuchai has also expanded its footprint into overseas markets.  In 2024, Yuchai sold 356,586 engines, further solidifying its position as a leading manufacturer and distributor of engines in China.  For more information, please visit http://www.cyilimited.com

Safe Harbor Statement:

This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe”, “expect”, “anticipate”, “project”, “targets”, “optimistic”, “confident that”, “continue to”, “predict”, “intend”, “aim”, “will” or similar expressions are intended to identify forward-looking statements. All statements other than statements of historical fact are statements that may be deemed forward-looking statements. These forward-looking statements, including, but not limited to, statements concerning China Yuchai’s and the joint venture’s operations, financial performance and condition, are based on current expectations, beliefs and assumptions which are subject to change at any time. China Yuchai cautions that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors such as government and stock exchange regulations, competition, political, economic and social conditions around the world and in China, including those discussed in China Yuchai’s Form 20-Fs under the headings “Risk Factors”, “Results of Operations” and “Business Overview” and other reports filed with the Securities and Exchange Commission from time to time. All forward-looking statements are applicable only as of the date they are made and China Yuchai specifically disclaims any obligation to maintain or update the forward-looking information, whether of the nature contained in this release or otherwise, in the future.

For more information:

Investor Relations
Kevin Theiss
Tel: +1-212-510-8922
Email: cyd@bluefocus.com 

China Unicom Beijing Powers World’s First Humanoid Robot Games with Smart 5G-A Network


BEIJING, CHINA – Media OutReach Newswire – 18 August 2025 – At the 2025 World Humanoid Robot Games which just kicked off, China Unicom Beijing provides full 5G-A network coverage outside and inside the event venue — Beijing National Speed Skating Oval. This cutting-edge network, characterized by its high uplink capacity, reliability, and security, is enabling over 500 robots from nearly 280 teams worldwide to compete at their best across athletic, performance, industrial, and healthcare contests. It is also significantly enhancing the experience for tens of thousands of spectators. Such robust 5G-A networks will transform society by propelling humanoid robots beyond competitions and into full-scale commercialization.

China Unicom at the World's First Humanoid Robot Games
China Unicom at the World’s First Humanoid Robot Games

The AI industry is developing rapidly. Multimodal and cross-device interactions are reshaping personal experiences, IoT connections are growing exponentially, and AI is now woven into the fabric of core production processes, completely redefining workflows. These embodied AI robots are a demanding AI application, requiring a specialized network that allows them to perceive their surroundings, make instant decisions, pinpoint their location precisely, and coordinate with other robots.

With the games already in play, China Unicom Beijing is delivering reliable, extensive, and high-uplink connectivity for both robots and spectators outside and inside the arena. Outside, a 5G-A 3D network coordinating 1:1 high and mid bands boosts peak uplink and downlink user-perceived rates to 4 Gbps and 11.2 Gbps, respectively. Inside, LampSite offers 300 MHz bandwidth, achieving a peak network speed of 2.4 Gbps.

“Our 5G-A networks currently serve users, and we’re upgrading them to support embodied AI as well,” said Qin Yang, Deputy General Manager of China Unicom Beijing. “Our 5G-A network for this event reflects this progress. It dedicates a channel for spectators and a dynamically scalable one for robots, realizing seamless connectivity for both spectators and robots even during peak usage. In the robot sector, 5G-A will also be key to enabling low-latency remote control.”

Samuel Chen, Vice President of Marketing for Huawei’s Wireless Network Product Line, said, “At the humanoid robot games, the network must support many robots, spectators, and live media streams. It needs to provide high uplink capacity, low latency, high reliability, and wide coverage.”

Inside the venue, a 5G-A digital indoor system has been developed utilizing 300 MHz ultra-high-bandwidth spectrum. It delivers an uplink speed above 100 Mbps, allowing multiple 4K machine vision streams to be uploaded without frame loss. It also ensures air interface latency remains below 20 ms, so robots can respond to commands instantly.

Outside the venue, a 5G-A 3D network coordinates 1:1 high and low bands to achieve downlink and uplink speeds of 10 Gbps and 4 Gbps, respectively. With this fast connectivity, 8K panoramic cameras merge footage live, media like CCTV upload UHD shallow-compressed signals in seconds, and crowds live stream and share videos without lag.

As the world’s first international sports event for humanoid robots, the games set the stage for a groundbreaking fusion of technology and athletics, signaling AI’s expansion into sports at scale. As the event’s exclusive global communications partner, China Unicom is dedicated to ensuring millisecond-level network response and zero downtime with its 5G-A, AI, and all-optical network expertise through collaboration with partners. Beyond the event, China Unicom aims to inject strong momentum into the robotics industry.

Hashtag: #Huawei

The issuer is solely responsible for the content of this announcement.

Baidui Cup grows into global stage for youth football in Beijing


BEIJING, CHINA – Media OutReach Newswire – 18 August 2025 – The 42nd “Baidui Cup” Football Tournament kicked off in the rain on the August 8th. It brought a refreshing coolness of summer to the young players and once again ignited a football fever in Beijing, the “Dual Olympic City”.

A player goes for goal during a Baidui Cup match, August 2025.
A player goes for goal during a Baidui Cup match, August 2025.

As 51-year-old Chinese football legend Yang Chen watched children playing joyfully at the ongoing Beijing youth football tournament, vivid memories of his own participation over four decades ago came flooding back.

“I really enjoy those exciting and delightful moments, running side by side with my young teammates, trying to perform our best, and pursuing victories. This is where my dream began,” noted the Beijing native, who participated in the first two editions of the tournament.

The Beijing youth football tournament is also known as the Baidui Cup. In 1984, 112 teams signed up for the inaugural event, while the number has expanded to over 1,000 in recent years.

Players vie for the ball during a Baidu Cup match, August 2025.
Players vie for the ball during a Baidu Cup match, August 2025.

This year, the 42nd edition of the Baidui Cup runs through August 8 to 17. “More kids are getting involved in this traditional tournament. They learn from each other and improve their skills through matches. Their passion shows the great football atmosphere here,” Yang said.

In the current tournament, young players competed on football fields across six districts in Beijing, while their parents and other family members cheered for them throughout, no matter whether it was rainy or sunny in the hot summer.

“The Baidui Cup is my most anticipated event in summer vacation. It is like a football party,” said the 10-year-old Li Jinglin during his fifth appearance at the tournament. “I started playing football as a left wing midfielder at the age of five. Two years ago, our goalkeeper got injured, and I replaced him and have stayed in that position since. I want to defend the victory for our team.”

Nine-year-old forward Wang Yibo, whose parents, grandmother and younger sister are his loyal fans, made his debut in the Baidui Cup after playing football for over two years.

“At first, I just hoped that he [Wang] could have better physical strength by attending football training sessions every week. Gradually, I found he was self-motivated to make progress step by step. I believe football will always accompany him as he grows up,” said Wang’s mother Guo Lele.

As the tournament has further expanded its influence in recent years, more talents from other cities and even the rest of the world have joined this youth football festival.

Coach Ma Zhiqiang brought his players from Rongjiang County, southwest China’s Guizhou Province to experience the Baidui Cup in Beijing for the first time this year. Rongjiang is the birthplace of China’s renowned Village Super League, also known as Cun Chao.

“My kids are all from the Chemin Primary School in Rongjiang. I have only been there for 10 months, but I already feel their tenacity and strong will to play. With no doubt, Cun Chao inspired them a lot, and they wish to play in front of their home audience in the future,” Ma said.

Children in mountainous areas generally have good leg strength but still need to polish their skills, particularly compared with young players from professional football clubs in Beijing. However, the performance of Rongjiang players at the Baidui Cup amazed everyone.

Ma remarked, “My team strictly implemented the game plan. In the first half, they concentrated on defense, while in the second half, they took advantage of their physical strength to make counter-attack. We are all excited to secure several victories here.”

Nine-year-old Lin Qihang, captain of the Rongjiang youth team, practices for more than three hours every day after school. He said, “Playing football made me more self-disciplined. Our trip to Beijing is an opportunity to learn from other teams and see a bigger world.”

Travelling from thousands of miles away, Zimbabwe’s 11-year-old Christiano Konono competed in the Baidui Cup with his teammates, who are all from Jadel Football Academy, a youth football club in Beijing founded by former professional player Walter Musanhu in 2019.

Jadel Football Academy dispatched five age-group teams to this summer’s Baidui Cup, with about 150 players from China, Zimbabwe, Japan and other countries and regions. This winter, Musanhu will lead his Chinese players to Zimbabwe to experience African football culture.

“I have so much love for the kids, and they need to be encouraged. I want these kids to achieve more than what I achieved as a football player. I want these kids to have the best memories in their lives,” remarked Musanhu.

Reflecting on the development of the Baidui Cup, Gao Jun, secretary of Beijing Football Association, said, “As the tournament grows in popularity, we organize it annually. There is simply no reason to stop.”

Indeed, the Baidui Cup has become an iconic youth football tournament pillared by the enthusiasm of young generations and the support from their families. Almost all elite Beijing native football players have showed their potential in the Baidui Cup, including former Chinese national team players Shao Jiayi and Liu Ying.

“A journey of more than 40 years is never easy. I hope more young players can stand out in the Baidui Cup and contribute to Chinese football and its related industries,” said Shao, currently the head coach of Qingdao West Coast in Chinese Super League.

Hashtag: #BaiduiCup

The issuer is solely responsible for the content of this announcement.

2025 IFSC Asian Youth Championships to Kick off on August 20th in Guiyang, Guizhou, 211 Young Athletes to Participate


GUIYANG, CHINA – Media OutReach Newswire – 18 August 2025 – Recently, the press conference for 2025 International Federation of Sport Climbing (IFSC) Asian Youth Championships was held at Guizhou Provincial Sports Bureau, announcing that the tournament will be held from August 20th to 24th at Guizhou Caihu International Climbing Center in Guanshanhu Park, Guiyang City. A total of 211 young Asian athletes will compete in six disciplines: men’s and women’s speed climbing, lead climbing, and bouldering.

The Guiyang Guanshanhu Park, where the 2025 International Federation of Sport Climbing (IFSC) Asian Youth Championships will be held.
The Guiyang Guanshanhu Park, where the 2025 International Federation of Sport Climbing (IFSC) Asian Youth Championships will be held.

This tournament is hosted by IFSC Asia and jointly organized by the Mountaineering Administrative Center of the General Administration of Sport of China, Chinese Mountaineering Association, Guizhou Provincial Sports Bureau, and Guiyang Municipal People’s Government. It has two age groups, U17 and U19, and is an A-level event certified by IFSC Asia. There are 40 athletes in Chinese team to participate in this competition, including two rising stars from Guizhou: Meng Shixue, who defended the U19 women’s speed gold medal at the 2025 World Youth Climbing Championships in Helsinki, Finland, and Wang Chunyouxuan, who won the U17 women’s speed bronze medal.

It is reported that Guanshanhu District in Guiyang City is a “National Ecological Civilization Construction Demonstration Zone”. In 2024, the excellent air quality rate reached 99.5%, the forest coverage rate was 45.96%, and the per capita park green area was17.42 square meters. Multiple indicators such as surface water quality and quality of drinking water sources are 100% up to standard, presenting a green picture of harmonious coexistence between man and nature.

The Guizhou Caihu International Climbing Center, where the event is held, is located in the core area of Guanshan Lake Park, known as the “Urban Green Lung”. As a standard IFS-certified competition venue, the wall structure integrates the advantages of domestic and foreign course design, with the angle accuracy error controlled within 0.5°The three different climbing walls are designed not only to meet the technical requirements of speed climbing, lead climbing, and bouldering, which are featured in Olympic Games, but also to ensure training safety thanks to the scientific protection system.

In recent years, Guanshanhu District has adopted the strategy of “leveraging sports events to drive regional tourism”, and has successively built 16 large-scale cultural and sports venues such as Guiyang Olympic Sports Center and Guanshanhu Ecological Sports Park. As the venue for the Asian Youth Championship, Guanshanhu District has carefully planned and upgraded its climbing facilities during the preparation process. It is worth mentioning that in the development of sport economy, Guanshanhu District is not limited to host one type of sport event, but covers various sports such as football, badminton, fencing, etc., building a colorful sports ecology. In terms of event planning, Guanshanhu District not only hosts international or Asian sports events, but also introduces preferential policies such as reducing venue rent to attract regional sports competitions to be held here and enriching venue operation to improve regional sports events quality.

As for this event, the organizers have elaborately planned a series of activities deeply integrated “event+culture+consumption”. During the competition, Guanshan Lake Park Ethnic Festival Square will launch a “Roadside Concert by the Climbing Wall”, pooling ethnic elements such as Dong Chorus and Miao Songs with modern popular music, welcoming friends from all over the world with the romantic genes of Guiyang’s “City of Music Loving “. An outdoor themed market integrating food, travel, entertainment, and shopping will be created around the competition venue, showcasing premium coffee, craft beer, exquisite dining, and original cultural and creative products, making spectators to enjoy an immersive and amazing “city tour” experience.

At present, the preparation work is steadily advancing, and a “Three-Dimensional Assurance Network” covering medical care, security, reception, and transportation has been built, striving to make every participant feel the warmth of home and the enthusiasm of Guiyang.

The issuer is solely responsible for the content of this announcement.

Tongcheng Travel Deepened Presence in the Mass Travel Market in 1H2025 Accumulated Number of Travelers Served Increased by 7.2% Yoy to 1,990.6 Million Adjusted Net Profit Surges 28.6% Yoy to RMB1,563.3 Million

Increased Mass Travel Consumption Drives Strong Growth in Core OTA Businesses
AI Technology Builds Smart Travel Experiences

HONG KONG, Aug. 18, 2025 /PRNewswire/ — Tongcheng Travel Holdings Limited (“Tongcheng Travel” or the “Company”, together with its subsidiaries the “Group”, stock code: 0780.HK), a leading comprehensive travel platform in China, today announced its unaudited consolidated results for the three months (“2Q 2025”) and six months ended 30 June 2025 (the “period under review” or “1H 2025”).

1H2025 Highlights with Year-on-year (“yoy“) Comparison

Strong Growth in Revenue and Adjusted Net Profit

  • Revenue increased by 11.5% yoy to RMB9,046.9 million
  • Adjusted EBITDA increased by 35.2% yoy to RMB2,344.6 million, adjusted EBITDA margin was 25.9%
  • Adjusted net profit increased by 28.6% yoy to RMB1,563.3 million; adjusted net margin was 17.3% for 1H 2025 and 16.6% for 2Q 2025

Sustained Growth in User Base and User Value

  • Monthly paying users (MPUs) increased by 9.2% yoy to 46.5 million
  • Annual paying users (APUs) increased by 10.2% yoy to 251.7 million, recorded a historic high
  • Twelve-month Accumulated Number of Travelers Served increased by 7.2% yoy to 1,990.6 million, strengthened the Group’s position in China mass travel market

Robust Performance in Core OTA Businesses

  • Revenue of core OTA business increased by 15.9% yoy to RMB7,800.2 million 
    • Revenue from transportation ticketing services increased by 11.6% yoy to RMB 3,881.2 million. International air ticket volume achieved historic high with nearly 30% yoy growth in 2Q 2025
    • Revenue from accommodation reservation services increased by 18.8% yoy to RMB2,561.0 million. Daily room nights sold reaching a record high in 2Q 2025
    • Revenue from other businesses increased by 24.1% yoy to RMB1,358.0 million

Mr. Ma Heping, Executive Director and Chief Executive Officer of Tongcheng Travel, said, “In 2Q 2025, China’s travel industry maintained its trajectory of high-quality development, driven by robust market demand. Facing the dynamic market, Tongcheng Travel remains highly attuned to market changes and responds swiftly to seize the emerging opportunities. By leveraging our in-depth user insights and ongoing product and service optimization, we strengthen our market presence and further enhance brand influence. Looking ahead, we remain highly committed to expanding our core OTA business. While consolidating our domestic market position, we will fully advance our outbound travel business to strengthen our brand influence in the global market. Besides, we will also fortify our hotel management business to enhance our influence across the travel industry chain, supporting the Company’s long-term growth.”

Focusing on the Mass Travel Market and Enhancing User Value

The mass travel market is shifting beyond traditional leisure-focused itineraries toward deeper experiential engagement and cultural immersion, driving the emergence of new travel scenarios. Through extensive travel product offerings and effective user engagement initiatives, the Group has achieved continuous growth in both our user base and user value. During the period under review, the Group’s average MPUs increased by 9.2% yoy to 46.5 million, while APUs recorded a historic high and reached 251.7 million with 10.2% yoy growth. Besides, the twelve-month Accumulated Number of Travelers Served increased by 7.2% yoy to 1,990.6 million. Leveraging the effective traffic strategies and exceptional operational capabilities, Tongcheng Travel further solidified its position in China’s mass market.

The Group expanded its user base through various channels. During the period under review, Weixin ecosystem continued to serve as the Group’s vital traffic source, with more emphasis placed on enhancing operational efficiency within the platform. Meanwhile, the Group’s standalone APP remained the core channel for acquiring new users. Targeting the younger generation, the Group rolled out a series of entertaining marketing campaigns centered on trending social events, further strengthening brand appeal among targeted users. Notably, DAUs of its APP continued to grow strongly and reached an all-time high before the May Day holiday. Meanwhile, the Group intensified efforts across social media platforms to engage with younger, experience-oriented users.

Tongcheng Travel strived to enhance user value and deepen user loyalty on its platform. During the period under review, the Group set up an exclusive hotline and a dedicated customer service team to improve responsiveness to user inquiries and ensure prompt resolution of corresponding issues. In the meantime, the Group expanded user privileges and benefits, which yielded remarkable improvement in user retention and loyalty. Furthermore, the Group leveraged high-impact cultural events to strengthen engagement with younger cohorts and enhance brand appeal to experience-driven users.

Strong Growth Potential in Mass Travel Consumption
Core OTA Business Maintained Growth Momentum

Tongcheng Travel’s core OTA business maintained strong growth momentum. During the period under review, total revenue of core OTA business increased by 15.9 yoy to RMB7,800.2 million. Revenue from the accommodation business increased by 18.8% yoy to RMB2,561.0 million, fueled by solid volume growth and enhanced monetization capability. In 2Q 2025, the Group actively tapped into emerging accommodation reservation scenarios, such as weekend getaways, concerts and sports events, driving daily room nights sold to record highs. Besides, the Group intensified its efforts to expand its presence in lower-tier cities by targeting high-value users, which led to increased market share and further solidified competitiveness in these regions. As for the international accommodation business, the Group is devoted to deepening cooperation with global suppliers and strengthening presence in regions that are popular among Chinese travelers.

The Group’s transportation business once again achieved solid results. During the period under review, revenue from transportation ticketing services increased by 11.6% yoy to RMB3,881.2 million. The growth was mainly attributable to the entrenched market position, coupled with the expanding portfolio of value-added products and services. Besides, the Group’s international air ticketing business volume achieved historic high in 2Q 2025, with nearly 30% year-on-year growth, underpinned by the Group’s effective growth strategies and enhanced operational efficiency. As for the train ticketing business, the Group remained concentrated on enhancing Huixing system and optimizing operational strategies to better address user needs. As such, the monetization capabilities of the train ticket business further improved this quarter, contributing to healthy revenue growth of the segment.

Tongcheng Travel’s other businesses also demonstrated exceptional performance. During the period under review, revenue from the other businesses increased by 24.1% yoy to RMB1,358.0 million, driven by the excellent performance of its hotel management business. As a key initiative of the strategic deployment across the travel industry chain, the Group’s asset-light hotel management business sustained its healthy growth trajectory in expanding geographic footprint across China. By the end of June 2025, the number of hotels in operation under the hotel management business platform of the Group has risen to over 2,700, with nearly 1,500 in the pipeline.

Embracing Frontier Technologies to Build a Smarter Travel Experience

Guided by the technology-driven corporate value, Tongcheng Travel proactively embraces frontier technologies and strategically integrates them into its business so as to enhance operational efficiency and deliver seamless travel experiences. During the period under review, the Group launched its AI-powered itinerary planner DeepTrip, which combines the supply chain capabilities on the Group’s platform with the reasoning capabilities of DeepSeek. The Group advanced its application in some business scenarios to improve its operational efficiency. For tailor-made tours, the Group integrated DeepTrip into the workflow to streamline the consulting phase, which enables users to easily access comprehensive destination information, thus reducing consulting time and enhancing user experience. Meanwhile, the Group leveraged DeepTrip to deliver marketing activities to users inquiring about travel itineraries, thereby facilitating their decision-making process.

Tongcheng Travel is dedicated to empowering industry partners by utilizing its profound internet expertise and advanced technologies so as to build a highly efficient ecosystem. During the period under review, the Group initiated a strategic partnership with Shandong Provincial Airport Management Group. By leveraging its technological strengths and platform advantages, the Group will support them in optimizing flight planning and enhancing operational efficiency. Additionally, the Group has strengthened strategic cooperation with Xi’an Xianyang International Airport, with plans to deepen cooperation in intermodal travel products, member benefit integration, and joint marketing initiatives.

Furthermore, HopeGoo, the new international online travel booking platform under Tongcheng Travel, has been in full operation. It provides reservation services in six key areas including flights, hotels, train tickets, attraction tickets, ferry tickets, and local activities, and supports payments in 16 currencies and multiple languages.

Looking ahead, Tongcheng Travel will remain highly committed to expanding its core OTA business by enhancing market share and brand influence. While solidifying its domestic market position, the Group will seize opportunities to fully advance its outbound travel business, thereby expanding its global market presence. The Group will also fortify its hotel management business to enhance its influence across the travel industry chain, which is pivotal to its long-term development. Finally, Tongcheng Travel will remain committed to best practices in corporate governance, environmental protection, and social responsibility to generate long-term value for its stakeholders.

-End-

About Tongcheng Travel Holdings Limited (HKSE Stock Code: 0780.HK)

Tongcheng Travel is a one-stop shop for users’ travel needs. With the mission “make travel easier and more joyful”, Tongcheng Travel offers a comprehensive and innovative selection of products and services covering nearly all aspects of travel, including transportation ticketing, accommodation reservation, tourist attraction ticketing, and products including package tour, self-guided tour and cruise, including a wide array of transportation and leisure travel scenarios primarily through its online platforms, which comprise its Tencent-based platforms, its proprietary mobile apps, quick apps and other channels.

As a technology-driven company, Tongcheng Travel leverages big data and AI capabilities to better understand the preferences and behaviors of users, thereby offering users customized products and services. With has a strategic focus on mass travel market in China, Tongcheng Travel capitalizes on its diversified traffic sources, product innovation capability and flexible operation strategies to expand its market presence. Through the in-depth understanding of user experience and advanced technological capabilities, Tongcheng Travel has been revolutionizing what consumers expect from the online travel industry, making the entire travel process more convenient, personalized and enjoyable than ever. Tongcheng Travel aims to develop and apply its advanced technology to transform from an online travel agency to intelligent travel assistant.

For more information, please visit the Group’s website at https://www.tongchengir.com/